GYENNO Science is a private medical technology company focused on central nervous system diseases, especially Parkinson’s and motor dysfunction. It develops AI- and robotics-enabled assistive devices and other healthcare products for patients.
Access to pre-IPO shares is available to accredited investors through UpMarket.
Latest Price
Previous Price
Series B-II 2021
How to Invest in Gyenno Science Through UpMarket
Gyenno Science shares are not on public exchanges. UpMarket provides accredited investors access through secondary market transactions.
Step 01
Verify accredited investor status
Confirm eligibility under SEC Rule 501 of Regulation D. Income or net worth threshold applies.
Step 02
Create an UpMarket account
Complete KYC/AML onboarding. Typically 1–2 business days. Licensed rep assigned on signup.
Step 03
Review available Gyenno Science offerings
Full offering memoranda and risk disclosures provided before any commitment is required.
Step 04
Complete subscription documents
Review and sign subscription agreement. All documents handled digitally through the platform.
Step 05
Fund your investment
Wire transfer or ACH. $50K minimum. Funds held in custodial account until close.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
2021
Series B+
2021
Series B-II
Why Investors Are Watching Gyenno Science
Product Milestone
Gyenno’s orthostatic-hypotension model reached 72% accuracy
A peer-reviewed PMC article reported a machine-learning model for acute orthostatic hypotension prediction with 72% accuracy on independent test data. The model used 17 features, with maximal SBP drop and DBP drop among the most important predictors.
Market Opportunity
AI health tools address a large R&D-intensive medtech market
WIPO said global corporate R&D spending reached almost USD 1.3 trillion in 2024, with R&D intensity rising to 5.5%. That backdrop supports demand for differentiated health-tech products that can justify continued development spending.
Competitive Moat
Predictive model puts proprietary feature engineering at center
The PMC study found the model’s top variables were ΔSBP, ΔDBP, and standing mean arterial pressure, indicating performance depends on clinical feature design. Its random-forest approach beat logistic regression and SVM, suggesting algorithm choice and domain data can create defensible differentiation.
Interested in Gyenno Science stock? Fill out the form above or sign up directly. Subject to availability. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers — legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. As of March 2026, Gyenno Science is a private company and does not trade on any public stock exchange. Accredited investors can access Gyenno Science shares through UpMarket, a FINRA-registered broker-dealer that specializes in pre-IPO investments.
Gyenno Science does not have a public stock price because it is privately held. The most recent known share price comes from its last funding round. Pre-IPO share prices on the secondary market may differ from the last round price depending on supply, demand, and market conditions.
Yes. Accredited investors can indicate interest in Gyenno Science shares through UpMarket by filling out the form on this page or creating an account at upmarket.co. All pre-IPO offerings are subject to availability and require a $50,000 minimum investment. UpMarket is a FINRA-registered broker-dealer and has brokered alternative investments since 2019.
Pre-IPO investments carry significant risks. Gyenno Science shares are illiquid, meaning there is no public market to sell them quickly. There is no guaranteed exit timeline or return. The investment is speculative in nature, and investors should be prepared for the possibility of total loss. Valuations of private companies can fluctuate substantially between funding rounds. Investors should consult their financial advisor and review all offering documents before investing.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
There are two primary exit paths for pre-IPO holdings: selling your shares on the secondary market to another buyer, or holding until the company completes an IPO or is acquired. Both paths are subject to transfer restrictions, company approval (right of first refusal), and market conditions. The timing of any exit is unpredictable, and investors should plan for a multi-year holding period.
The minimum investment for most pre-IPO offerings on UpMarket is $50,000. This amount may vary depending on the specific offering and share availability. There are no fees to create an UpMarket account or browse available investments. Investors only pay transaction-related fees when they complete an investment.
UpMarket's valuation estimate of is derived from a proprietary model that incorporates multiple data sources: funding round data (Caplight), revenue estimates (Sacra), secondary market pricing, and public company comparables. The model applies a private company discount to the public comp multiple to account for illiquidity and information asymmetry. This estimate is not investment advice and may differ substantially from the price at which shares actually trade.
GYENNO Science develops AI- and robotics-enabled medical technology for central nervous system diseases, and its orthostatic-hypotension model reached 72% accuracy, signaling progress in Parkinson’s and motor dysfunction care — accredited investors can access Gyenno Science stock through UpMarket.